Iris cysts are benign lesions that arise from iris tissue and are seen clinically in cyst or elevated form. They can be primary, with no etiological cause, or secondary, with etiological cause. Primary iris cysts are divided into epithelial and stromal…
With more than 3 million procedures performed annually in the U.S., cataract surgery is nearly a rite of passage. Technological advances including phacoemulsification and premium IOLs have all contributed to making cataract surgery one of the safest and most effective procedures performed. However, the post-surgical drop regimen has remained a largely unchanged and cumbersome process for both patients and office staff.As an “in the trenches” surgeon working to provide the best care for my patients, I believe the time has arrived to confidently adopt the practice of administering post-surgical pharmacological treatment intraocularly. Patients benefit from the convenience and affordability, and my staff is relieved of many of the calls we receive from patients and pharmacies. To best serve the needs of my patients, I adopted Tri-Moxi-Vanc therapy (Imprimis Pharmaceuticals) into my surgical armamentarium. The compounded medication consists of a proprietary formulation of triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin in a sterile package. The product is ordered from an accredited compounding pharmacy and delivered directly to the office.
New devices in ophthalmology range from the disruptive to the disappointing, with lots of incremental gains in between. Capital equipment manufacturers often offer significant upgrades to lasers and phaco machines, but these can come with a significant…
A major factor in optimizing cataract surgery outcomes is obtaining reliable measurements of the cornea. Much of the pathology that compromises this reliability is readily apparent. Being able to identify and address more subtle abnormalities in a time…
A previously healthy 19-year-old college student was referred to the New England Eye Center for evaluation after returning from Indonesia where she had studied abroad and suffered a severe illness requiring hospitalization. She had blurred vision in bo…
So far in 2015, four different ophthalmic products in phase 3 clinical trials failed to meet their primary endpoints. Ocular Surgery News spoke with three of these companies to find out what happened and how they responded. Their stories offer a telling glimpse at the challenges and opportunities companies face when endpoints are missed in clinical trials as part of the overall innovation cycle.“Private companies often simply learn from their experience and make appropriate adjustments to their research and business plan. They continue on as long as their investors are optimistic they will eventually create value,” OSN Chief Medical Editor Richard L. Lindstrom, MD, said. “Public companies must disclose any material event in a timely fashion and usually see a significant fall in their share price, usually in the 20% to 50% range, but it can be even more if it is an FDA trial not approved by a panel.”